Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Sell
23
LEXX Quote, Financials, Valuation and Earnings
Last price:
$1.08
Seasonality move
:
-5.62%
Day range:
$1.04 - $1.10
52-week range:
$1.01 - $4.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
32.73x
P/B ratio:
2.96x
Volume:
94.6K
Avg. volume:
94.5K
1-year change:
-70%
Market cap:
$21.1M
Revenue:
$464.3K
EPS (TTM):
-$0.59
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Lexaria Bioscience has 548.15% upside to fair value with a price target of $7.00 per share.
LEXX vs. S&P 500
-
Over the past 5 trading days, Lexaria Bioscience has underperformed the S&P 500 by -8.88% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Lexaria Bioscience does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lexaria Bioscience has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Lexaria Bioscience reported revenues of $174K.
Earnings Growth
-
Lexaria Bioscience has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Lexaria Bioscience reported earnings per share of -$0.15.
Enterprise value:
14.2M
EV / Invested capital:
2.10x
Price / LTM sales:
32.73x
EV / EBIT:
--
EV / Revenue:
26.99x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.88x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$523.2K
Return On Assets:
-107.34%
Net Income Margin (TTM):
-1784.18%
Return On Equity:
-118.15%
Return On Invested Capital:
-118.15%
Operating Margin:
-1581.04%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-02-28 | 2024-02-28 | 2025-02-28 | 2024-02-28 | 2025-02-28 | |
| Income Statement | ||||||
| Revenue | $328.6K | -- | $525.9K | -- | $174K | |
| Gross Profit | $250K | -- | $523.2K | -- | $174K | |
| Operating Income | -$6.2M | -- | -$9.4M | -- | -$2.8M | |
| EBITDA | -$6.1M | -- | -$9.3M | -- | -$2.7M | |
| Diluted EPS | -$1.17 | -- | -$0.59 | -- | -$0.15 | |
| Period Ending | 2021-02-28 | 2022-02-28 | 2023-02-28 | 2024-02-28 | 2025-02-28 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $10.9M | $10.6M | $4M | -- | $7.7M | |
| Total Assets | $12.2M | $11.4M | $4.9M | -- | $8.7M | |
| Current Liabilities | $399.4K | $165.5K | $223.1K | -- | $1.8M | |
| Total Liabilities | $469.6K | $194.6K | $223.1K | -- | $1.9M | |
| Total Equity | $11.7M | $11.2M | $4.6M | -- | $6.8M | |
| Total Debt | $7.5K | $7.9K | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-02-28 | 2024-02-28 | 2025-02-28 | 2024-02-28 | 2025-02-28 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.9M | -- | -$7.4M | -- | -$1.5M | |
| Cash From Investing | -$155.5K | -- | -$157.3K | -- | -$27.9K | |
| Cash From Financing | -$22.4K | -- | $9.4M | -- | $11.7K | |
| Free Cash Flow | -$5.1M | -- | -$7.5M | -- | -$1.5M | |
LEXX
Sector
Market Cap
$21.1M
$33.9M
Price % of 52-Week High
24.32%
44.2%
Dividend Yield
0%
0%
Shareholder Yield
-16.88%
-0.74%
1-Year Price Total Return
-70%
-40.43%
Beta (5-Year)
1.008
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.12
200-day SMA
Sell
Level
$2.29
Bollinger Bands (100)
Sell
Level
1.32 - 2.02
Chaikin Money Flow
Sell
Level
-92.5M
20-day SMA
Sell
Level
$1.29
Relative Strength Index (RSI14)
Sell
Level
36.47
ADX Line
Sell
Level
14.99
Williams %R
Buy
Level
-89.7059
50-day SMA
Sell
Level
$1.42
MACD (12, 26)
Sell
Level
-0.12
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
178.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (21.3771)
Sell
CA Score
(Annual)
Level (-2.8144)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (10.3673)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Stock Forecast FAQ
In the current month, LEXX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LEXX average analyst price target in the past 3 months is $7.00.
-
Where Will Lexaria Bioscience Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lexaria Bioscience share price will rise to $7.00 per share over the next 12 months.
-
What Do Analysts Say About Lexaria Bioscience?
Analysts are divided on their view about Lexaria Bioscience share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lexaria Bioscience is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Lexaria Bioscience's Price Target?
The price target for Lexaria Bioscience over the next 1-year time period is forecast to be $7.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LEXX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lexaria Bioscience is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of LEXX?
You can purchase shares of Lexaria Bioscience via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lexaria Bioscience shares.
-
What Is The Lexaria Bioscience Share Price Today?
Lexaria Bioscience was last trading at $1.08 per share. This represents the most recent stock quote for Lexaria Bioscience. Yesterday, Lexaria Bioscience closed at $1.08 per share.
-
How To Buy Lexaria Bioscience Stock Online?
In order to purchase Lexaria Bioscience stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is a Millionaire-Maker Stock?
From time to time, investors will run across the term…
5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Sell
50
QDEL alert for May 10
QuidelOrtho [QDEL] is down 0.22% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
